Natera (NTRA) Quick Ratio: History & Chart

Natera, Inc.(NTRA)

Medical - Diagnostics & Research · Austin, TX

$410.35+1.88 (+0.46%)

Delayed quote: Oct 2, 2026, 4:00 PM EDT

About Natera, Inc.

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Austin, TX

6,138 employees

www.natera.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Steven Leonard Chapman

View full financials

NTRA Quick Ratio (Acid-Test) Metrics

QUICK RATIO (ACID-TEST)

2.85

QUICK RATIO (ACID-TEST) AVG TTM

3.13

QUICK RATIO (ACID-TEST) AVG 3Y

3.64

QUICK RATIO (ACID-TEST) AVG 5Y

3.63

QUICK RATIO (ACID-TEST) AVG 10Y

3.13

QUICK RATIO (ACID-TEST) AVG 15Y

N/A

QUICK RATIO (ACID-TEST) AVG 20Y

N/A

CURRENT VS TTM AVG

-8.72%

CURRENT VS 3Y AVG

-21.63%

CURRENT VS 5Y AVG

-21.43%

CURRENT VS 10Y AVG

-8.97%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

1.28

median of 97 covered companies

CURRENT VS SECTOR MEDIAN

+122.94%

vs the sector median at left

NAME	MARKET CAP	QUICK RATIO (ACID-TEST)	TTM	3Y	5Y
Natera, Inc. (NTRA)	$58.77B	2.85	3.13	3.64	3.63
Cencora, Inc. (COR)vs ›	$60.13B	0.58	0.54	0.53	0.55
Boston Scientific Corporation (BSX)vs ›	$63.32B	0.74	0.86	0.89	1.02
Cardinal Health, Inc. (CAH)vs ›	$53.47B	0.49	0.49	0.52	0.54
Edwards Lifesciences Corporation (EW)vs ›	$49.03B	3.77	3.27	2.83	2.71
Becton, Dickinson and Company (BDX)vs ›	$48.72B	0.51	0.69	0.70	0.80
Agilent Technologies, Inc. (A)vs ›	$47.38B	1.56	1.54	1.63	1.68
Humana Inc. (HUM)vs ›	$46.63B	1.74	0.58	0.57	0.58
Cigna Corporation (CI)vs ›	$71.48B	0.74	0.72	0.68	0.69
Teva Pharmaceutical Industries Limited (TEVA)vs ›	$46.04B	0.67	0.78	0.74	0.73

NAME

MARKET CAP

QUICK RATIO (ACID-TEST)

TTM

Natera, Inc. (NTRA)

$58.77B

2.85

3.13

3.64

3.63

Cencora, Inc. (COR)vs ›

$60.13B

0.58

0.54

0.53

0.55

Boston Scientific Corporation (BSX)vs ›

$63.32B

0.74

0.86

0.89

1.02

Cardinal Health, Inc. (CAH)vs ›

$53.47B

0.49

0.52

0.54

Edwards Lifesciences Corporation (EW)vs ›

$49.03B

3.77

3.27

2.83

2.71

Becton, Dickinson and Company (BDX)vs ›

$48.72B

0.51

0.69

0.70

0.80

Agilent Technologies, Inc. (A)vs ›

$47.38B

1.56

1.54

1.63

1.68

Humana Inc. (HUM)vs ›

$46.63B

1.74

0.58

0.57

0.58

Cigna Corporation (CI)vs ›

$71.48B

0.74

0.72

0.68

0.69

Teva Pharmaceutical Industries Limited (TEVA)vs ›

$46.04B

0.67

0.78

0.74

0.73

Quick Ratio (Acid-Test) FAQ

What is the quick ratio (acid-test) for Natera, Inc. (NTRA)?

The quick ratio (acid-test) for NTRA stock is 2.85.

Is Natera, Inc.'s quick ratio (acid-test) high or low?

The quick ratio (acid-test) of 2.85 is 21% below its 5-year average of 3.63, near the low end of its 5-year range (2.83–5.82).

What is the TTM average quick ratio (acid-test) for Natera, Inc. (NTRA)?

The TTM average quick ratio (acid-test) for NTRA stock is 3.13.

What is the 3Y average quick ratio (acid-test) for Natera, Inc. (NTRA)?

The 3Y average quick ratio (acid-test) for NTRA stock is 3.64.

What is the 5Y average quick ratio (acid-test) for Natera, Inc. (NTRA)?

The 5Y average quick ratio (acid-test) for NTRA stock is 3.63.

What is the 10Y average quick ratio (acid-test) for Natera, Inc. (NTRA)?

The 10Y average quick ratio (acid-test) for NTRA stock is 3.13.

DATE	QUICK RATIO (ACID-TEST)
2026-06-30	2.85
2026-03-31	2.83
2025-12-31	3.24
2025-09-30	3.13
2025-06-30	3.58
2025-03-31	3.74
2024-12-31	3.87
2024-09-30	4.23
2024-06-30	4.01
2024-03-31	3.98
2023-12-31	3.96
2023-09-30	4.23
2023-06-30	3.69
2023-03-31	3.74
2022-12-31	3.79
2022-09-30	2.95
2022-06-30	3.46
2022-03-31	4.13
2021-12-31	4.87
2021-09-30	5.82
2021-06-30	3.59
2021-03-31	4.60
2020-12-31	4.23
2020-09-30	4.57
2020-06-30	3.68
2020-03-31	2.73
2019-12-31	2.84
2019-09-30	2.26
2019-06-30	2.42
2019-03-31	1.73
2018-12-31	1.99
2018-09-30	2.32
2018-06-30	1.56
2018-03-31	1.68
2017-12-31	1.63
2017-09-30	1.75
2017-06-30	1.18
2017-03-31	1.42
2016-12-31	1.74
2016-09-30	2.12
2016-06-30	2.39
2016-03-31	2.87
2015-12-31	3.02
2015-09-30	6.67
2015-06-30	1.85
2015-03-31	2.61
2014-12-31	3.18
2014-09-30	1.23
2014-06-30	0.00
2014-03-31	1.16
2013-12-31	1.63
2013-09-30	0.00
2013-03-31	0.00

DATE

QUICK RATIO (ACID-TEST)

2026-06-30

2.85

2026-03-31

2.83

2025-12-31

3.24

2025-09-30

3.13

2025-06-30

3.58

2025-03-31

3.74

2024-12-31

3.87

2024-09-30

4.23

2024-06-30

4.01

2024-03-31

3.98

2023-12-31

3.96

2023-09-30

4.23

2023-06-30

3.69

2023-03-31

3.74

2022-12-31

3.79

2022-09-30

2.95

2022-06-30

3.46

2022-03-31

4.13

2021-12-31

4.87

2021-09-30

5.82

2021-06-30

3.59

2021-03-31

4.60

2020-12-31

4.23

2020-09-30

4.57

2020-06-30

3.68

2020-03-31

2.73

2019-12-31

2.84

2019-09-30

2.26

2019-06-30

2.42

2019-03-31

1.73

2018-12-31

1.99

2018-09-30

2.32

2018-06-30

1.56

2018-03-31

1.68

2017-12-31

1.63

2017-09-30

1.75

2017-06-30

1.18

2017-03-31

1.42

2016-12-31

1.74

2016-09-30

2.12

2016-06-30

2.39

2016-03-31

2.87

2015-12-31

3.02

2015-09-30

6.67

2015-06-30

1.85

2015-03-31

2.61

2014-12-31

3.18

2014-09-30

1.23

2014-06-30

0.00

2014-03-31

1.16

2013-12-31

1.63

2013-09-30

0.00

2013-03-31

0.00

Quick Ratio (Acid-Test): 2.85

NTRA Quick Ratio

NTRA Average Quick Ratio (Acid-Test) Chart

NTRA Current vs Average Quick Ratio (Acid-Test) Chart

NTRA Quick Ratio (Acid-Test) Metrics

NTRA Competitors' Quick Ratio (Acid-Test)

Liquidity Comparison

Quick Ratio (Acid-Test) Formula & Definition

Quick Ratio (Acid-Test) FAQ

NTRA Quick Ratio (Acid-Test) History

Related Metrics